Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -351,472 | -413,645 | -583,852 | -417,320 | -349,848 |
| Depreciation Amortization | 15,525 | 40,141 | 61,794 | 35,860 | 14,703 |
| Accounts receivable | -40,211 | -2,360 | 0 | 0 | N/A |
| Accounts payable and accrued liabilities | -190 | -3,167 | -6,476 | 8,000 | -3,717 |
| Other Working Capital | -54,329 | -19,422 | 3,828 | -8,001 | -19,112 |
| Other Operating Activity | 125,741 | 7,217 | 157,949 | 43,952 | 83,555 |
| Operating Cash Flow | $-304,936 | $-391,236 | $-366,757 | $-337,509 | $-274,419 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -241,373 | -140,218 | -10,358 | -500 | -127,987 |
| PPE Investments | -3,846 | -6,888 | -30,584 | -78,162 | -13,065 |
| Net Acquisitions | N/A | -1,000 | N/A | N/A | N/A |
| Purchase Of Investment | N/A | N/A | N/A | -1,000 | 0 |
| Sale Of Investment | 95,824 | 136,607 | 10,472 | 128,188 | 56,166 |
| Purchase Sale Intangibles | N/A | N/A | N/A | -21,229 | 0 |
| Other Investing Activity | -406 | -747 | 0 | -21,229 | 0 |
| Investing Cash Flow | $-149,801 | $-12,246 | $-30,470 | $27,297 | $-84,886 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,884 | N/A | N/A | N/A | N/A |
| Debt Issued | 0 | 0 | 258,700 | 174,125 | 338,500 |
| Debt Repayment | -1,160 | -64 | -77 | -58 | 0 |
| Common Stock Issued | 400,782 | 190,203 | 110,397 | 60,501 | 169,991 |
| Other Financing Activity | -2,265 | 91,491 | 189,321 | -955 | -3,048 |
| Financing Cash Flow | $400,241 | $281,630 | $558,341 | $233,613 | $505,443 |
| Exchange Rate Effect | 15 | -23 | -292 | 284 | 48 |
| Beginning Cash Position | 143,912 | 265,787 | 104,965 | 181,280 | 35,094 |
| End Cash Position | 89,431 | 143,912 | 265,787 | 104,965 | 181,280 |
| Net Cash Flow | $-54,481 | $-121,875 | $160,822 | $-76,315 | $146,186 |
| Free Cash Flow | |||||
| Operating Cash Flow | -304,936 | -391,236 | -366,757 | -337,509 | -274,419 |
| Capital Expenditure | -3,846 | -6,888 | -30,584 | -78,162 | -33,563 |
| Free Cash Flow | -308,782 | -398,124 | -397,341 | -415,671 | -307,982 |